10 Cheap Biotech Stocks to Invest in Now

4. Voyager Therapeutics, Inc. (NASDAQ:VYGR)

P/E Ratio: 8.58 

Voyager Therapeutics, Inc. (NASDAQ:VYGR) develops gene therapies for neurological diseases like Alzheimer’s, Parkinson’s, and ALS. The company’s unique TRACER platform allows for the creation of novel AAV capsids that can better cross the blood-brain barrier, enabling more targeted delivery of gene therapies to the central nervous system.

As of September 30, 2024, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has a cash position of $345 million, extending its runway into 2027. Its pipeline includes four wholly-owned programs and 14 partnered programs, with partnerships with Novartis, Neurocrine, and Alexion. The company recently completed enrollment for its VY7523 trial for Alzheimer’s disease with data expected in 2025. The company’s strong financial position and promising Alzheimer’s program make it an attractive investment in the biotech sector.

Analysts hold a consensus Strong Buy rating on the stock. Analysts set a 12-month average price target for Voyager Therapeutics, Inc. (NASDAQ:VYGR) of $18.00, with a high of $30.00 and a low of $14.00. This represents a 256.44% increase from the current price of $5.05.